Meeting
2013 ASCO Annual Meeting
Pemetrexed-carboplatin adjuvant chemotherapy with or without gefitinib in resected stage IIIA-N2 non-small cell lung cancer harbouring EGFR mutations: A randomized phase II study.
Authors
Si-Yu Wang
Sun Yat-sen University Cancer Center, Guangzhou, China
Si-Yu Wang , Wei Ou , Ning Li , Haibo Sun , Liang Zhang , Qin Fang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Lung Cancer - Non-small Cell Local-regional/Small Cell/Other Thoracic Cancers
Track
Lung Cancer
Sub Track
Adjuvant Therapy
Citation
J Clin Oncol 31, 2013 (suppl; abstr 7519)
DOI
10.1200/jco.2013.31.15_suppl.7519
Abstract #
7519
Poster Bd #
13
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
Updated survival outcomes of NEJ005/TCOG0902, a randomized phase II study of concurrent (C) versus sequential alternating (S) gefitinib and chemotherapy in previously untreated non-small cell lung cancer (NSCLC) with sensitive epidermal growth factor receptor (EGFR) mutations.
First Author: Satoshi Oizumi
Poster
2014 ASCO Annual Meeting
Randomized phase II study of concurrent gefitinib and chemotherapy versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer (NSCLC) with sensitive EGFR mutations: NEJ005/TCOG0902.
First Author: Satoshi Oizumi
Poster
2022 ASCO Annual Meeting
A phase II study of osimertinib in combination with platinum plus pemetrexed in patients with EGFR-mutated, advanced non–small cell lung cancer: The OPAL study (NEJ032C/LOGIK1801).
First Author: Atsushi Nakamura
Poster
2012 ASCO Annual Meeting
Epidermal growth factor receptor mutation status and adjuvant chemotherapy in resected advanced non-small cell lung cancer.
First Author: Si-Yu Wang